JIN YANG PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5,410 KRW | 0.00% |
|
+0.19% | -12.60% |
| Apr. 09 | Jin Yang Pharmaceutical Co., Ltd.'s Equity Buyback Plan Extended till April 9, 2025. | CI |
| 2023 | Jin Yang Pharmaceutical Co. Ltd.'s Equity Buyback Plan Extended till December 22, 2024. | CI |
| Sales 2022 | 76.26B 55.44M | Sales 2023 | 94.11B 68.42M | Capitalization | 66.81B 48.57M |
|---|---|---|---|---|---|
| Net income 2022 | 12.31B 8.95M | Net income 2023 | 12.66B 9.2M | EV / Sales 2022 | 1.05 x |
| Net Debt 2022 | 9.49B 6.9M | Net Debt 2023 | 4.34B 3.16M | EV / Sales 2023 | 0.76 x |
| P/E ratio 2022 |
6.61
x | P/E ratio 2023 |
5.27
x | Employees | 220 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 59.84% |
More Fundamentals
* Assessed data
More news
| 1 week | +0.19% | ||
| Current month | -8.92% | ||
| 1 month | -9.68% | ||
| 3 months | -8.92% | ||
| 6 months | -10.43% | ||
| Current year | -12.60% |
1 week
5 380.00
5 500.00
1 month
5 350.005 980.00
Current year
5 350.006 430.00
1 year
5 350.006 900.00
3 years
5 220.009 230.00
5 years
2 935.0011 450.00
10 years
2 935.0011 450.00
| Managers | Title | Age | Since |
|---|---|---|---|
Jae-Jun Choi
CEO | Chief Executive Officer | 54 | - |
Yoon-Hwan Choi
CHM | Chairman | 87 | - |
Jong-Gu Im
BRD | Director/Board Member | 66 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yoon-Hwan Choi
CHM | Chairman | 87 | - |
Jae-Jun Choi
CEO | Chief Executive Officer | 54 | - |
Jong-Gu Im
BRD | Director/Board Member | 66 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 5,410 | 0.00% | 16,179 |
| 24-04-25 | 5,410 | -0.92% | 7,565 |
| 24-04-24 | 5,460 | +0.18% | 6,160 |
| 24-04-23 | 5,450 | +0.55% | 10,289 |
| 24-04-22 | 5,420 | +0.37% | 6,706 |
End-of-day quote Korea S.E., April 25, 2024
More quotes
JIN YANG PHARMACEUTICAL CO., LTD is a Korea-based company mainly engaged in the manufacturing and distributing of medicine and medicine supplies. The Companyâs products consist of drugs for the circulation systems, digestive organs and the central nervous systems, antibiotics, metabolic drugs, and others including antihistaminic agents, anti-inflammatory analgesic drugs, antimicrobials, muscle relaxants, psychotropic agents, high blood pressure medicines, diabetes medicines, injection medicines, skin disease medicines, nutritional supplements, anemia medicines, dental care drugs, ophthalmology care drugs and others. The Company distributes its products within domestic market and to overseas markets.
Sector
Pharmaceuticals
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -12.60% | 42.51M | |
| +19.62% | 43.78B | |
| +20.44% | 21.89B | |
| +10.86% | 14.45B | |
| +13.07% | 13.63B | |
| +37.46% | 11.49B | |
| -8.59% | 6.85B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +8.46% | 5.06B |
- Stock Market
- Equities
- A007370 Stock
